It was also only a 6 week trial. It was also the 3rd indication for which 2591 has showed efficacy across multiple aspects in a severely debilitating disease
Ann: Phase 2 trial shows significant improvements in Angelman, page-42
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.17 |
Change
-0.390(2.68%) |
Mkt cap ! $1.806B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $14.11 | $2.688M | 188.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 181 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.18 | 654 | 12 |
View Market Depth
| Last trade - 14.01pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |